Pliant Therapeutics, Inc., situated in South San Francisco, CA, is pioneering advancements in the treatment of fibrosis through targeted integrin therapies. Their mission is to offer hope to fibrosis patients by developing innovative therapies that stem from a deep understanding of the molecular mechanisms driving fibrotic diseases.
With a team of seasoned experts in fibrosis and drug development, Pliant Therapeutics is at the forefront of developing tissue-specific therapies. Their extensive pipeline includes two clinical stage programs, notably featuring the first oral, selective small molecule integrin inhibitor.
At Pliant, the focus is on revolutionizing fibrosis treatment, recognizing the vital role patients play in their journey towards healing. By striving to unlock safer and more effective therapies, Pliant Therapeutics aims to make a significant impact in the field of fibrotic diseases.
Generated from the website content
